BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24879476)

  • 1. Asian Versus Non-Asian Outcomes in Nasopharyngeal Carcinoma: A North American Population-based Analysis.
    Hamilton SN; Ho C; Laskin J; Zhai Y; Mak P; Wu J
    Am J Clin Oncol; 2016 Dec; 39(6):575-580. PubMed ID: 24879476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients?
    Corry J; Fisher R; Rischin D; Peters LJ
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):63-71. PubMed ID: 16226395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: A subset with better overall survival.
    Tian YH; Zou WH; Xiao WW; Zeng L; Yuan X; Bai L; Lu T; Tian Y; Han F
    Head Neck; 2016 Aug; 38(8):1152-7. PubMed ID: 27220062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
    Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
    BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: A retrospective study.
    Katano A; Takahashi W; Yamashita H; Yamamoto K; Ando M; Yoshida M; Saito Y; Abe O; Nakagawa K
    Medicine (Baltimore); 2018 May; 97(18):e0502. PubMed ID: 29718841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer.
    Verma V; Allen PK; Simone CB; Gay HA; Lin SH
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1383-1391. PubMed ID: 29118230
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
    Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study.
    Hutajulu SH; Howdon D; Taroeno-Hariadi KW; Hardianti MS; Purwanto I; Indrasari SR; Herdini C; Hariwiyanto B; Ghozali A; Kusumo H; Dhamiyati W; Dwidanarti SR; Tan IB; Kurnianda J; Allsop MJ
    PLoS One; 2021; 16(2):e0246638. PubMed ID: 33577563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
    Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
    Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.
    Goshtasbi K; Lehrich BM; Birkenbeuel JL; Abiri A; Harris JP; Kuan EC
    Otolaryngol Head Neck Surg; 2021 Jul; 165(1):93-103. PubMed ID: 33231508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior cervical lymph node metastasis as the valuable prognostic factor for stage IVA/IVB nasopharyngeal carcinoma treated with induction chemotherapy followed by concurrent chemo-radiotherapy.
    Thephamongkhol K; Setakornnukul J; Rojwatkarnjana S; Chansilpa Y
    Int J Biol Markers; 2014 Dec; 29(4):e387-94. PubMed ID: 25198554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.